UNCLASSIFIABLE MYELODYSPLASTIC SYNDROME DEFINED BY A CYTOGENETIC ABNORMALITY: A REAL-LIFE STUDY.

EHA Library, Victor-Emmanuel Brett, 325656

USING TISSUE MICROARRAY TO DETECT INFLAMMASOME SIGNALING COMPONENTS THAT CONTRIBUTE TO THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROME

EHA Library, Tony Kurian, 325657

PIM INHIBITORS INDUCE THE FERROPTOSIS VIA HIF1A/GPX4 PATHWAY IN HEMATOLOGICAL MALIGNANT CELLS

EHA Library, Rong Fu, 325658

BMSCS REGULATE THE FUNCTION OF NK CELL BY CD155/TIGIT/CD226 PATHWAY IN MDS PATIENTS

EHA Library, Zhaoyun Liu, 325659

PHARMACOLOGIC INHIBITORS OF CDK4/CDK6 EXERT ANTI-NEOPLASTIC EFFECTS ON CMML CELLS AND SYNERGIZE WITH THE MULTI-KINASE INHIBITOR PONATINIB IN NEOPLASTIC MONOCYTES

EHA Library, Max V. John, 325660

THE PIVOTAL ROLE OF WEE1 AND PARP-1 IN MYELODYSPLASTIC SYNDROME (MDS): A NEW STRATEGY FOR THE TARGETED THERAPY OF MDS

EHA Library, Seiichi Okabe, 325661

AZACITIDINE SEQUENCED WITH RIGOSERTIB DOWNREGULATES NEGATIVE REGULATORS OF HEMATOPOIESIS INCLUDING MULTIPLE MAPK PATHWAYS IMPACTING STEMNESS/DIFFERENTIATION OF MDS-L CELLS WITH CLINICAL IMPLICATIONS

EHA Library, Richa Rai, 325662

PHENOTYPIC AND GENETIC FEATURES OF MYELODYSPLASTIC SYNDROME (MDS) BONE MARROW (BM) DERIVED MESENCHYMAL STROMAL CELLS (MSC) FOR DISEASE PROGNOSIS AND THERAPY

EHA Library, Zhiyong Poon, 325663

PREVALENCE OF UBA1 MUTATIONS IN MDS/CMML PATIENTS WITH SYSTEMIC INFLAMMATORY AND AUTO-IMMUNE DISEASE

EHA Library, Lin-Pierre Zhao, 325664

MESENCHYMAL STROMAL CELLS AS A POTENTIAL THERAPEUTIC TOOL IN ENHANCING RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS

EHA Library, Tamara Jiménez, 325665

SIMPLE FLOW CYTOMETRY IMMUNOPHENOTYPING APPROACH PREDICTS THE DEVELOPMENT OF MYELOID NEOPLASMS IN PATIENTS WITH CCUS

EHA Library, Dragan Jevremovic, 325666

VENETOCLAX AND AZACITIDINE COMBINATION IN CHEMOTHERAPY INELIGIBLE PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASMS, ANTECEDENT MYELODYSPLASTIC SYNDROMES OR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Vinod A. Pullarkat, 325667

EFFICACY OF IMETELSTAT IS INDEPENDENT OF MOLECULAR SUBTYPES IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA)

EHA Library, Uwe Platzbecker, 325668

A MACHINE LEARNING APPROACH TO PREDICTING RISK OF MYELODYSPLASTIC SYNDROME

EHA Library, Ashwath Radhachandran, 325669

THERAPY-RELATED MDS; A WIDE DEFINITION THAT NEEDS NARROWING

EHA Library, Daniel Berggren, 325670

RESULTS OF A PHASE I/II CLINICAL TRIAL COMBINING GUADECITABINE WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Casey L OConnell, 325671

ASXL1 MUTATIONS PREDICT A POOR RESPONSE TO DARBEPOETIN ALFA IN ANEMIC PATIENTS WITH LOW-RISK MDS: A MULTICENTER, PHASE II STUDY

EHA Library, Motoshi Ichikawa, 325672

BENEFIT OF CONTINUING LUSPATERCEPT THERAPY IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO DID NOT ACHIEVE RED BLOOD CELL TRANSFUSION INDEPENDENCE BY WEEK 25 IN THE MEDALIST STUDY

EHA Library, Ulrich Germing, 325673

PREDICTORS OF HYPOMETHYLATING AGENT DISCONTINUATION AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Amer M. Zeidan, 325674

UPDATED SAFETY AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF PATIENTS WITH TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES: PHASE 1B RESULTS

EHA Library, Andrew Wei, 325675

SIMILAR SURVIVAL AND GENETIC FEATURES BETWEEN CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND LOWER-RISK MYELODYSPLASTIC SYNDROME

EHA Library, Eun-Ji Choi, 325676

CHARACTERISTICS AND OUTCOMES OF MYELODYSPLASTIC SYNDROMES (MDS) WITH ISOLATED THROMBOCYTOPENIA: A RETROSPECTIVE, NATIONAL, COHORT STUDY

EHA Library, Konstantinos Liapis, 325677

LUSPATERCEPT REDUCES RED BLOOD CELL TRANSFUSIONS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES REGARDLESS OF BASELINE TRANSFUSION BURDEN IN THE MEDALIST STUDY

EHA Library, Guillermo Garcia-Manero, 325678

FLOW-CYTOMETRIC ASSESSMENT OF BONE MARROW MICROENVIRONMENT IN LOW-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Juri Alessandro Giannotta, 325679

A CIBERSORTX-BASED IMMUNE-CELL SCORING SYSTEM COULD INDEPENDENTLY PREDICT PROGNOSIS OF MYELODYSPLASTIC SYNDROME PATIENTS

EHA Library, Yu-Hung Wang, 325680

VENETOCLAX COMBINED WITH AZACITIDINE IN THE TREATMENT OF RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER STUDY

EHA Library, Hongyan Tong, 325681

UPDATED OVERALL SURVIVAL OF ELTANEXOR FOR THE TREATMENT OF PATIENTS WITH HYPOMETHYLATING AGENT REFRACTORY MYELODYSPLASTIC SYNDROME

EHA Library, Sangmin Lee, 325682

EARLY DECREASE IN VARIANT ALLELE FREQUENCY IN PERIPHERAL BLOOD WITH DROPLET DIGITAL PCR IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS RESPONDING TO AZACITIDINE

EHA Library, Johanna Illman, 325683

COMPARISON OF DOSE MODIFICATION STRATEGIES TO ADDRESS EXPECTED HEMATOLOGIC TOXICITIES IN TREATMENT-NAÏVE HIGHER-RISK (HR) MDS PATIENTS TREATED WITH VENETOCLAX + AZACITIDINE

EHA Library, Uwe Platzbecker, 325684

PROGNOSTIC IMPACT OF BONE MARROW FIBROSIS IN PRIMARY MYELODYSPLASTIC SYNDROMES

EHA Library, Maria Florencia Russo, 325685

DOSE SELECTION OF PEVONEDISTAT + AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA: A MODEL-BASED ANALYSIS

EHA Library, Xiaofei Zhou, 325686

CLINICAL FEATURES OF MYELOID NEOPLASMS WITH DDX41 MUTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Ziqi Wan, 325687

QUANTIFYING THE HEALTHCARE RESOURCE USE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS IN ENGLAND

EHA Library, James Farrell, 325688

HIGH TRANSFERRIN SATURATION PREDICTS INFERIOR CLINICAL OUTCOMES IN PATIENTS WITH MDS

EHA Library, Jennifer Teichman, 325689

CIRCULATING MICRORNA MIR-99B AND MIR-125A IN MYELODYSPLASTIC SYNDROME-NONINVASIVE DIAGNOSTIC AND PROGNOSTIC BIOMARKERS

EHA Library, Inga MANDAC ROGULJ, 325690

THE R-IPSS DOES NOT SEEM TO ACCURATELY PREDICT FATAL EVENTS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH AUTOIMMUNE DISEASES

EHA Library, Jose Miguel Torregrosa-Díaz, 325691

IMPACT OF TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML) ON OVERALL SURVIVAL (OS) AMONG PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN THE UNITED STATES OF AMERICA (USA)

EHA Library, Vamsi Kota, 325692

CHANGES IN THE CONCENTRATION OF TUMOR NECROSIS FACTOR TNF- IN BLOOD SERUM AND THE LEVEL OF CD33+ SUBSTRATE CELLS IN THE BONE MARROW OF PATIENTS WITH MYELODYSPLASTIC SYNDROME.

EHA Library, Halyna Starodub, 325693

GENOMIC CORRELATES OF RESPONSE TO SELINEXOR IN MULTIPLE MYELOMA FROM THE BOSTON STUDY REVEAL A PREDICTIVE SIGNATURE

EHA Library, Paula Restrepo, 325694

DEVELOPMENT OF NEXT-GENERATION ANTITUMOR ANTIBODIES ARMED WITH BRIDGING-BITE TO ADVANCE ANTI-MYELOMA IMMUNOTHERAPY

EHA Library, Tatsuya Konishi, 325695

ISB 1342: A FIRST-IN-CLASS CD38 T CELL ENGAGER FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Mario Perro, 325696

A NOVEL ONCOLYTIC LENTIVIRAL VECTOR FOR THE TARGETED AND THERAPEUTIC IFNΒ- EXPRESSION IN MULTIPLE MYELOMA

EHA Library, Eleni Kalafati, 325697

LONG-ACTING STARCH NANOPARTICLE DRUG DELIVERY SYSTEM TO TREAT MULTIPLE MYELOMA

EHA Library, Sauli Vuoti, 325698

KNOCKOUT OF CD96 OR TIGIT USING CRISPR/CAS9 ENHANCES NK INDUCED CYTOTOXICITY AND CYTOKINE PRODUCTION IN THE PRESENCE OF CD155 EXPRESSING MYELOMA CELLS

EHA Library, John Daly, 325699

INDUCTION OF ELOTUZUMAB’S ADCC ACTIVITY BY TH1-LIKE GAMMA DELTA T CELLS TOWARDS OSTEOCLASTS AS WELL AS MYELOMA CELLS

EHA Library, Takeshi Harada, 325700

PROGRESSION AND DISSEMINATION OF EXPERIMENTAL MULTIPLE MYELOMA IS ASSOCIATED WITH LOSS OF INNATE AND ADAPTIVE IMMUNE-MEDIATED TUMOR CONTROL

EHA Library, Zoltán Kellermayer, 325701

SEA-BCMA, AN ENHANCED ANTIBODY FOR MULTIPLE MYELOMA, COMBINES EFFECTIVELY WITH MULTIPLE THERAPEUTIC MODALITIES

EHA Library, Heather Van Epps, 325702

MELFLUFEN RAPIDLY ACCUMULATES WITHIN TUMOR CELLS AND DISTRIBUTES AN ALKYLATING PAYLOAD TO THE NUCLEUS AND MITOCHONDRIA

EHA Library, Kenneth Flanagan, 325703

STUDY OF BONE MARROW MESENCHYMAL STEM CELLS REGULATING NK CELLS FUNCTION THROUGH TIGIT/ CD226 IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 325704

TUMOR ASSOCIATED MACROPHAGES INHIBIT CD8+T CELLS IMMUNE RESPONSES VIA PD-1/PD-L1 PATHWAY IN MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 325705

COEXISTENCE OF MYELODYSPLASTIC SYNDROMES (MDS) AND MULTIPLE MYELOMA (MM)

EHA Library, Lenka Pavlistova, 325706

CLINICAL AND PHENOTYPIC FEATURES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS: THE POSSIBLE LACK OF CD38 EXPRESSION.

EHA Library, Fabrizio Accardi, 325707

INTEGRATIVE APPROACH TO FIND PREDICTIVE MARKERS OF RESPONSE TO DARATUMUMAB IN MULTIPLE MYELOMA

EHA Library, Camille Pochard, 325708

ALKBH5 PROMOTES THE PATHOGENESIS OF MULTIPLE MYELOMA THROUGH REGULATING LNCRNA SNHG15

EHA Library, Wu Qiuling, 325709

INTESTINAL MICROBIOTA AS A PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA

EHA Library, Alba Rodríguez-García, 325710

LNCRNA MSTRG.29039.1 PROMOTES PROLIFERATION BY SPONGING HSA-MIR-12119 VIA JAK2/STAT3 PATHWAY IN MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 325711

DYSREGULATED EXOSOMAL MICRORNA EXPRESSION IN BONE MARROW MICROENVIRONMENT OF MULTIPLE MYELOMA, EXTRAMEDULLARY MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA

EHA Library, Jana Gregorová, 325712

LACK OF CD56 AS A POOR PROGNOSTIC MARKER IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Andreas Epameinondas Koumpis, 325713

TRANSCRIPTOMIC ANALYSIS IDENTIFIED GENE CO-EXPRESSION AND CORRELATION WITH MULTIPLE MYELOMA PROGRESSION.

EHA Library, Olayinka Adebayo, 325714

THE ADIPONECTIN RECEPTOR AGONIST, ADIPORON, EXERTS ANTIPROLIFERATIVE AND PRO-APOPTOTIC EFFECTS THROUGH THE REGULATION OF ADIPORS/AMPK/ACC PATHWAY ON HUMAN MULTIPLE MYELOMA CELLS

EHA Library, Jing Zhang, 325715

DECIPHERING CLINICAL IMPLICATION OF DYSREGULATED SERUM MICRORNAS IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A RESULT OF COMPREHENSIVE MICRORNA PROFILING BY DEEP SEQUENCING

EHA Library, Harshini Sriram, 325716

THE CLINICAL UTILITY OF A PLASMA MIRNA SIGNATURE IN MULTIPLE MYELOMA BONE DISEASE

EHA Library, Aristea-Maria Papanota, 325717

METABOLIC ADAPTATIONS IN CARFILZOMIB-RESISTANT MULTIPLE MYELOMA CELLS - A PILOT STUDY

EHA Library, Dominik Dytfeld, 325718

SINGLE CELL MULTI-OMIC ANALYSIS AND IMMUNE CELL TYPE PROFILING OF MULTIPLE MYELOMA WITH T(4;14).

EHA Library, Sanjay de Mel, 325719

LONG-TERM FOLLOW-UP RESULTS OF A MULTICENTER FIRST-IN-HUMAN STUDY OF THE DUAL BCMA/CD19 TARGETED FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Juan Du, 325720

FINAL ANALYSIS OF THE PHASE 3 TOURMALINE-MM1 STUDY INVESTIGATING IXAZOMIB + LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD (PRD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS (PTS)

EHA Library, PAUL RICHARDSON, 325721

UPDATED CARTITUDE-1 RESULTS OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Saad Z. Usmani, 325722

FCRH5 TARGET EXPRESSION IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CEVOSTAMAB IN AN ONGOING PHASE I DOSE ESCALATION STUDY

EHA Library, Teiko Sumiyoshi, 325723

EFFECTS OF SELINEXOR ON PREVIOUSLY TREATED MULTIPLE MYELOMA (MM) WITH RAS-MUTATIONS

EHA Library, Christopher Walker, 325724

MODULATION OF SOLUBLE B-CELL MATURATION ANTIGEN LEVELS BY TECLISTAMAB AND TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Suzette Girgis, 325725

SUBGROUP ANALYSIS ON RESPONSE TO INDUCTION THERAPY WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYLEOMA

EHA Library, Elias K. Mai, 325726

DARATUMUMAB PLUS CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE INDUCTION THERAPY IN MULTIPLE MYELOMA FOLLOWED BY DARATUMUMAB MAINTENANCE: END-OF-STUDY RESULTS FROM LYRA

EHA Library, Robert M. Rifkin, 325727

ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—OPTIMAL DOSE AND UPDATED EFFICACY AND SAFETY RESULTS

EHA Library, ROMAN HAJEK, 325728

TIME TO BEST RESPONSE CORRELATES WITH OUTCOME IN THE RANDOMIZED COMPARISON BETWEEN KRD AND KTD FOLLOWED BY K MAINTENANCE OR OBSERVATION (AGMT-MM02 TRIAL)

EHA Library, Heinz Ludwig, 325729

CILTACABTAGENE AUTOLEUCEL FOR TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA: ADJUSTED COMPARISON OF CARTITUDE-1 OUTCOMES VERSUS REAL WORLD CLINICAL PRACTICE OBSERVED IN GERMAN REGISTRY

EHA Library, Hartmut Goldschmidt, 325730

MELFLUFEN PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA EXPOSED AND/OR REFRACTORY TO PRIOR ALKYLATORS – A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES

EHA Library, Paula Rodríguez-Otero, 325731

EFFICACY AND SAFETY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE BASED ON REFRACTORY STATUS TO LENALIDOMIDE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE BOSTON STUDY

EHA Library, Xavier Leleu, 325732

SUBGROUP ANALYSIS: EFFICACY AND SAFETY OF ORAL PANOBINOSTAT IN COMBINATION WITH SC BORTEZOMIB AND ORAL DEXAMETHASONE IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS > 75 YEARS OF AGE

EHA Library, Fredrik Schjesvold, 325733

SURVIVAL AMONG OLDER PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA TREATED WITH SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (XVD) IN THE BOSTON STUDY

EHA Library, Thierry Facon, 325734

COMPARISON OF OUTCOMES WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-1 VERSUS STANDARD OF CARE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS IN CLINICAL TRIALS OF DARATUMUMAB

EHA Library, Katja Weisel, 325735

MATCHING ADJUSTED INDIRECT COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY

EHA Library, Katja Weisel, 325736

FIRST-LINE THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: FINAL RESULTS OF THE OBSERVATIONAL STUDY FIRST-NIS

EHA Library, Holger Nückel, 325737

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS

EHA Library, Thierry Facon, 325738

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: IKEMA SUBGROUP ANALYSIS

EHA Library, Ivan Spicka, 325739

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS KD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF TIME TO NEXT TREATMENT, TIME TO PROGRESSION, AND PROGRESSION-FREE SURVIVAL FOR NEXT THERAPY

EHA Library, Saad Z. Usmani, 325740

DEVELOPMENT OF ANTIBODY RESPONSE TO SARS-COV-2 FOLLOWING ASYMPTOMATIC INFECTION IN PATIENTS WITH PLASMA CELL DISORDERS ON IMMUNOMODULATORY THERAPY

EHA Library, Wei Yee Chan, 325741

CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PIVOTAL PHASE 2 KARMMA STUDY

EHA Library, Salomon Manier, 325742

REAL-WORLD DURATION OF TREATMENT (DOT) WITH LENALIDOMIDE-DEXAMETHASONE (RD)-BASED REGIMENS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): OUTCOMES FROM THE GLOBAL INSIGHT MM STUDY

EHA Library, Noemi Puig, 325743

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS

EHA Library, Meletios-Athanasios Dimopoulos, 325744

A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION

EHA Library, María-Victoria Mateos, 325745

POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SAFETY SUBANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

EHA Library, Katja Weisel, 325746

SURVIVAL AND OUTCOMES OF NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS STRATIFIED BY TRANSPLANT STATUS DIAGNOSED BETWEEN 2007-2018: REAL-WORLD ANALYSIS FROM THE CANADIAN MYELOMA RESEARCH GROUP DATABASE

EHA Library, Hira Mian, 325747

COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS CONVENTIONAL TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 325748

A MULTINATIONAL CHART REVIEW OF REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Martin Kortüm, 325749

PULMONARY FUNCTION TESTS REVEAL UNRECOGNIZED LUNG DYSFUNCTION AND HAVE INDEPENDENT PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS

EHA Library, Despoina Fotiou, 325750

EFFECTIVENESS AND SAFETY OF IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) OUTSIDE OF A CLINICAL TRIAL: FINAL ANALYSIS OF THE ‘USE VIA EARLY ACCESS TO IXAZOMIB’ (UVEA IXA) STUDY

EHA Library, Heinz Ludwig, 325751

OVERVIEW AND EVOLUTION OF TREATMENT LINES IN MULTIPLE MYELOMA FROM 2014 TO 2018: A RETROSPECTIVE STUDY USING THE FRENCH NATIONAL CLAIM DATABASE (SNDS)

EHA Library, Aurore Perrot, 325752

EXOSOMAL CIRCRNA CACNG2 IS A NOVEL BIOMARKER FOR MM-RELATED CARDIAC DISEASES

EHA Library, Manya Yu, 325753

AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA: IMPROVEMENT IN IMMEDIATE RESULTS USING NON-CRYOPRESERVED STEM CELLS

EHA Library, Pilar Dutari, 325754

CLINICAL VALUE OF MINIMAL RESIDUAL DISEASE ASSESSED BY MULTIPARAMETER FLOW CYTOMETRY IN AMYLOID LIGHT CHAIN AMYLOIDOSIS

EHA Library, Juan Li, 325755